"Drug Hypersensitivity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
Descriptor ID |
D004342
|
MeSH Number(s) |
C20.543.206 C25.100.468
|
Concept/Terms |
Drug Hypersensitivity- Drug Hypersensitivity
- Drug Hypersensitivities
- Hypersensitivities, Drug
- Drug Allergy
- Allergies, Drug
- Drug Allergies
- Hypersensitivity, Drug
- Allergy, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug Hypersensitivity".
Below are MeSH descriptors whose meaning is more specific than "Drug Hypersensitivity".
This graph shows the total number of publications written about "Drug Hypersensitivity" by people in this website by year, and whether "Drug Hypersensitivity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 1 | 0 | 1 |
1994 | 2 | 1 | 3 |
1995 | 1 | 0 | 1 |
1998 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2004 | 2 | 1 | 3 |
2005 | 0 | 1 | 1 |
2006 | 0 | 1 | 1 |
2008 | 3 | 1 | 4 |
2010 | 1 | 0 | 1 |
2013 | 1 | 1 | 2 |
2016 | 2 | 0 | 2 |
2017 | 1 | 0 | 1 |
2021 | 1 | 0 | 1 |
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Hypersensitivity" by people in Profiles.
-
Burke MJ, Zalewska-Szewczyk B. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. Future Oncol. 2022 Mar; 18(10):1285-1299.
-
Murphy KR, Patel NC, Ein D, Hudelson M, Kodoth S, Marshall GD, Parikh P, Blaiss MS. Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines. Ann Allergy Asthma Immunol. 2021 Apr; 126(4):319-320.
-
Burke MJ, Devidas M, Maloney K, Angiolillo A, Schore R, Dunsmore K, Larsen E, Mattano LA, Salzer W, Winter SS, Carroll W, Winick NJ, Loh ML, Raetz E, Hunger SP, Bleyer A. Severe pegaspargase hypersensitivity reaction rates (grade ?3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. Leuk Lymphoma. 2018 07; 59(7):1624-1633.
-
Burke MJ, Rheingold SR. Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2017 03; 58(3):540-551.
-
Cheraghi N, Yasuda M, Deng A, Mailhot J. Azathioprine hypersensitivity presenting as neutrophilic dermatosis and erythema nodosum. Cutis. 2016 Jul; 98(1):E7-9.
-
Fantasia HC. Updated treatment guidelines for gonorrhea infections. Nurs Womens Health. 2013 Jun-Jul; 17(3):231-5.
-
Rhyee SH, Bienia-Kenton L, Collins A. Allergies to analgesic medications in ED patients. Am J Emerg Med. 2013 Feb; 31(2):431-2.
-
Critchfield AS, Lievense SP, Raker CA, Matteson KA. Group B Streptococcus prophylaxis in patients who report a penicillin allergy: a follow-up study. Am J Obstet Gynecol. 2011 Feb; 204(2):150.e1-8.
-
Paltiel M, Gober LM, Deng A, Mikdashi J, Alexeeva I, Saini SS, Gaspari AA. Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab. Arch Dermatol. 2008 Sep; 144(9):1190-4.
-
Hughes S, Hughes A, Brothers C, Spreen W, Thorborn D. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat. 2008 Apr-Jun; 7(2):121-9.